Kisspeptin治疗多囊卵巢综合征:临床前模型与患者的促性腺激素及排卵反应
该研究在三种雄激素诱导的PCOS大鼠模型及12例无排卵PCOS妇女中评估kisspeptin-54(KP-54)的促性腺激素与排卵反应。部分无排卵模型及妇女中KP-54可刺激生殖激素分泌并诱导排卵,但疗效不完全。
要点
- KP-54可刺激部分PCOS模型和妇女的LH/FSH分泌及排卵。
- 疗效因模型/个体而异,部分无反应或发生脱敏。
- 提示PCOS无排卵管理需个体化,部分患者可能受益于kisspeptin治疗。
核心结论
- KP-54在部分无排卵PCOS临床前模型和妇女中可刺激生殖激素分泌并诱导排卵,但疗效不完全。
研究设计与样本
- 三种雄激素暴露不同发育窗口的PCOS大鼠模型:PNA(N=20)、NeNA(N=20)、PWA(N=20)。
- 成年后每日皮下注射KP-54(100 μg/kg)或溶媒11天,每模型每处理N=10。
- 探索性队列:12例无排卵PCOS妇女,皮下注射KP-54 6.4–12.8 nmol/kg,每日两次,共21天。
主要发现
- 所有PCOS模型均显示生殖指标失调,但仅NeNA和PWA大鼠无排卵。
- 无排卵NeNA大鼠对KP-54显示显著LH和FSH反应(P < 0.05),并恢复排卵。
- PWA大鼠重复注射KP-54后LH分泌减弱,未能排卵。
- PCOS妇女中KP-54引起LH小幅上升(P < 0.05),血清雌二醇相应升高(P < 0.05)。
- 2例妇女出现优势卵泡生长并排卵,1例卵泡生长但未排卵,另1例发生脱敏,其余无卵泡反应。
关键数值与推荐
- 大鼠KP-54剂量:100 μg/kg,皮下注射,每日一次,共11天。
- 妇女KP-54剂量:6.4–12.8 nmol/kg,皮下注射,每日两次,共21天。
- PCOS妇女诊断依据鹿特丹标准。
临床怎么用
- kisspeptin治疗可能作为部分PCOS无排卵妇女的个体化选项,但需识别反应者。
局限性
- 大鼠模型仅部分再现PCOS临床特征。
- 临床研究为探索性原理验证,样本量小(N=12)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can kisspeptin treatment induce gonadotrophin responses and ovulation in preclinical models and anovulatory women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Kisspeptin administration in some anovulatory preclinical models and women with PCOS can stimulate reproductive hormone secretion and ovulation, albeit with incomplete efficacy. WHAT IS KNOWN ALREADY: PCOS is a prevalent, heterogeneous endocrine disorder, characterized by ovulatory dysfunction, hyperandrogenism and deregulated gonadotrophin secretion, in need of improved therapeutic options. Kisspeptins (encoded by Kiss1) are master regulators of the reproductive axis, acting mainly at GnRH neurons, with kisspeptins being an essential drive for gonadotrophin-driven ovarian follicular maturation and ovulation. Altered Kiss1 expression has been found in rodent models of PCOS, although the eventual pathophysiological role of kisspeptins in PCOS remains unknown. STUDY DESIGN, SIZE, DURATION: Gonadotrophin and ovarian/ovulatory responses to kisspeptin-54 (KP-54) were evaluated in three preclinical models of PCOS, generated by androgen exposures at different developmental windows, and a pilot exploratory cohort of anovulatory women with PCOS. PARTICIPANTS/MATERIALS, SETTING, METHODS: Three models of PCOS were generated by exposure of female rats to androgens at different periods of development: PNA (prenatal androgenization; N = 20), NeNA (neonatal androgenization; N = 20) and PWA (post-weaning androgenization; N = 20). At adulthood (postnatal day 100), rats were subjected to daily treatments with a bolus of KP-54 (100 μg/kg, s.c.) or vehicle for 11 days (N = 10 per model and treatment). On Days 1, 4, 7 and 11, LH and FSH responses were assessed at different time-points within 4 h after KP-54 injection, while ovarian responses, in terms of follicular maturation and ovulation, were measured at the end of the treatment. In addition, hormonal (gonadotrophin, estrogen and inhibin B) and ovulatory responses to repeated KP-54 administration, at doses of 6.4-12.8 nmol/kg, s.c. bd for 21 days, were evaluated in a pilot cohort of anovulatory women (N = 12) diagnosed with PCOS, according to the Rotterdam criteria. MAIN RESULTS AND THE ROLE OF CHANCE: Deregulated reproductive indices were detected in all PCOS models: PNA, NeNA and PWA. Yet, anovulation was observed only in NeNA and PWA rats. However, while anovulatory NeNA rats displayed significant LH and FSH responses to KP-54 (P < 0.05), which rescued ovulation, PWA rats showed blunted LH secretion after repeated KP-54 injection and failed to ovulate. In women with PCOS, KP-54 resulted in a small rise in LH (P < 0.05), with an equivalent elevation in serum estradiol levels (P < 0.05). Two women showed growth of a dominant follicle with subsequent ovulation, one woman displayed follicle growth but not ovulation and desensitization was observed in another patient. No follicular response was detected in the other women. LIMITATIONS, REASONS FOR CAUTION: While three different preclinical PCOS models were used in order to capture the heterogeneity of clinical presentations of the syndrome, it must be noted that rat models recapitulate many but not all the features of this condition. Additionally, our pilot study was intended as proof of principle, and the number of participants is low, but the convergent findings in preclinical and clinical studies reinforce the validity of our conclusions. WIDER IMPLICATIONS OF THE FINDINGS: Our first-in-rodent and -human studies demonstrate that KP-54 administration in anovulatory preclinical models and women with PCOS can stimulate reproductive hormone secretion and ovulation, albeit with incomplete efficacy. As our rat models likely reflect the diversity of PCOS phenotypes, our results argue for the need of personalized management of anovulatory dysfunction in women with PCOS, some of whom may benefit from kisspeptin-based treatments. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by research agreements between Ferring Research Institute and the Universities of Cordoba and Edinburgh. K.S. was supported by the Wellcome Trust Scottish Translational Medicine and Therapeutics Initiative (STMTI). Some of this work was undertaken in the MRC Centre for Reproductive Health which is funded by the MRC Centre grant MR/N022556/1. M.T.-S. is a member of CIBER Fisiopatología de la Obesidad y Nutrición, which is an initiative of Instituto de Salud Carlos III. Dr Mannaerts is an employee of Ferring International PharmaScience Center (Copenhagen, Denmark), and Drs Qi, van Duin and Kohout are employees of the Ferring Research Institute (San Diego, USA). Dr Anderson and Dr Tena-Sempere were recipients of a grant support from the Ferring Research Institute, and Dr Anderson has undertaken consultancy work and received speaker fees outside this study from Merck, IBSA, Roche Diagnostics, NeRRe Therapeutics and Sojournix Inc. Dr Skorupskaite was supported by the Wellcome Trust through the Scottish Translational Medicine and Therapeutics Initiative 102419/Z/13/A. The other authors have no competing interest.
引用
- Romero-Ruiz A, Skorupskaite K, Gaytan F, et al. Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome. Hum Reprod. 2019. PMID: 31820802. doi:10.1093/humrep/dez205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。